Wize Pharma to change name to Mawson Infrastructure Group Inc.
#Acquisition
Wize Pharma set for switch to Bitcoin mining
#Acquisition #Investment
Wize Pharma merges with Australian Bitcoin miner Cosmos
#Acquisition #Investment
Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
#Customers
Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020
#Partners
Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model
#Partners
Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
#Customers
Wize Pharma's Strategic Transaction Partner Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients
#Partners #Investment
Wize Pharma Completes Bonus BioGroup Strategic Transaction
#Acquisition #Investment
Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
#Customers
Wize Pharma Executes Agreements for Strategic Transaction With Bonus BioGroup
#Investment #Partners
Wize Pharma Lenders Convert $760,000 of Loans Into Equity
#Investment
Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology
#Partners
Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A
#Partners
Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals;Companies to Develop Cannabinoid Ophthalmic Treatments
#Partners
Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019
#Partners #Investment
Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis
#Customers
Wize Pharma's CEO Noam Danenberg Increases Stake in Company
undefined
Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer
#Management Changes
LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary
#Customers
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
#Partners
Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
#Partners
Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
#Investment, Expand
Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
#Customers
Wize Pharma, Inc. Announces $4.45 Million Private Placement
#Investment
Wize Pharma Appoints Ellen Lubman to its Advisory Board
#Management Changes
Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board
#Partners
Wize Pharma Signs Distribution Agreement in China for LO2A
#Partners
Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
#Customers
Wize Pharma to Present at 3rd Annual Disruptive Growth & Healthcare Conference in New York City on May 8, 2018
#Investment
Wize Pharma Completes Patient Enrollment in Phase II Study of LO2A for Treatment of Patients With CCH
#Customers
Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
#Customers
Wize Pharma Announces Dr. Joseph Tauber, Key Opinion Leader in Dry Eye, Joins Scientific Advisory Board
#Management Changes
Wize Pharma Announces Reverse Stock Split Effective March 5, 2018
#Public Trading
Wize Pharma Announces Expected Exercise of Investment Rights and Warrants for Total Proceeds of $1.14 Million
#Investment
Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
#Investment #Expand
Wize Announces Closing of Merger
#Acquisition #Public Trading